Wolverine Asset Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-47,895
| Closed | -$162K | – | 1866 |
|
|
2018
Q3 | $162K | Buy |
47,895
+19,484
| +69% | +$70.2K | ﹤0.01% | 1218 |
|
|
2018
Q2 | $106K | Hold |
28,411
| – | – | ﹤0.01% | 1180 |
|
|
2018
Q1 | $116K | Sell |
28,411
-655
| -2% | -$3.05K | ﹤0.01% | 1207 |
|
|
2017
Q4 | $135K | Buy |
29,066
+12,472
| +75% | +$68.7K | ﹤0.01% | 1132 |
|
|
2017
Q3 | $117K | Sell |
16,594
-2,406
| -13% | -$17.3K | ﹤0.01% | 1076 |
|
|
2017
Q2 | $137K | Buy |
+19,000
| New | +$119K | ﹤0.01% | 1005 |
|
|
2016
Q1 | – | Sell |
-5,751
| Closed | -$29K | – | 1778 |
|
|
2015
Q4 | $29K | Sell |
5,751
-83,675
| -94% | -$398K | ﹤0.01% | 1251 |
|
|
2015
Q3 | $314K | Buy |
89,426
+39,086
| +78% | +$262K | 0.01% | 803 |
|
|
2015
Q2 | $502K | Buy |
50,340
+48,300
| +2,368% | +$518K | 0.01% | 645 |
|
|
2015
Q1 | $25K | Sell |
2,040
-1,000
| -33% | -$12.9K | ﹤0.01% | 1410 |
|
|
2014
Q4 | $43K | Sell |
3,040
-3,700
| -55% | -$57.3K | ﹤0.01% | 1438 |
|
|
2014
Q3 | $92K | Sell |
6,740
-300
| -4% | -$4.59K | ﹤0.01% | 1336 |
|
|
2014
Q2 | $108K | Hold |
7,040
| – | – | ﹤0.01% | 1131 |
|
|
2014
Q1 | $119K | Sell |
7,040
-600
| -8% | -$9.05K | ﹤0.01% | 1059 |
|
|
2013
Q4 | $98K | Sell |
7,640
-26,000
| -77% | -$311K | ﹤0.01% | 1466 |
|
|
2013
Q3 | $339K | Buy |
33,640
+20,000
| +147% | +$178K | 0.01% | 916 |
|
|
2013
Q2 | $101K | Buy |
+13,640
| New | +$107K | ﹤0.01% | 1414 |
|
Wolverine Asset Management's KERX Position: Q4 2018 in Review
Wolverine Asset Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 47,895 shares — an estimated $162K sold.
Wolverine Asset Management first reported a position in KERX in Q2 2013 and held it in 17 quarters. The position peaked at $502K in Q2 2015. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Wolverine Asset Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Wolverine Asset Management sold 47,895 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $162K.
- Wolverine Asset Management first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 17 quarters.
- Wolverine Asset Management's Keryx Biopharmaceuticals Inc position peaked at $502K in Q2 2015.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Wolverine Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.